148 related articles for article (PubMed ID: 427774)
1. New ribonucleotide reductase inhibitors with antineoplastic activity.
Elford HL; Wampler GL; van't Riet B
Cancer Res; 1979 Mar; 39(3):844-51. PubMed ID: 427774
[No Abstract] [Full Text] [Related]
2. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
3. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity.
van't Riet B; Wampler GL; Elford HL
J Med Chem; 1979 May; 22(5):589-92. PubMed ID: 458812
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Tihan T; Elford HL; Cory JG
Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
7. Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents.
Elford HL; Van't Riet B; Wampler GL; Lin AL; Elford RM
Adv Enzyme Regul; 1980; 19():151-68. PubMed ID: 6175187
[No Abstract] [Full Text] [Related]
8. Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice.
Novotny L; Rauko P; Liska J; Elford HL; Szekeres T
Cancer Lett; 2006 Feb; 233(1):178-84. PubMed ID: 15885888
[TBL] [Abstract][Full Text] [Related]
9. DNA-protective activity of new ribonucleotide reductase inhibitors.
Rauko P; Romanova D; Miadokova E; Macakova K; Novotny L; Elford HL; Szekeres T
Anticancer Res; 1997; 17(5A):3437-40. PubMed ID: 9413183
[TBL] [Abstract][Full Text] [Related]
10. Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA.
Raichurkar AV; Kulkarni VM
J Med Chem; 2003 Oct; 46(21):4419-27. PubMed ID: 14521406
[TBL] [Abstract][Full Text] [Related]
11. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
Mayhew CN; Phillips JD; Greenberg RN; Birch NJ; Elford HL; Gallicchio VS
Stem Cells; 1999; 17(6):345-56. PubMed ID: 10606163
[TBL] [Abstract][Full Text] [Related]
13. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
14. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy.
Szekeres T; Fritzer-Szekeres M; Elford HL
Crit Rev Clin Lab Sci; 1997; 34(6):503-28. PubMed ID: 9439883
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ribonucleotide reductase by caracemide.
Moore EC; Loo TL
Cancer Treat Rep; 1984 Oct; 68(10):1293-4. PubMed ID: 6395952
[TBL] [Abstract][Full Text] [Related]
16. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
Carter GL; Cory JG
Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
[TBL] [Abstract][Full Text] [Related]
17. [Quantum-chemical studies on the mechanisms of inhibition of ribonucleotide reductase by aryl hydroxamic acids].
Xu X; Luo YF; Cai WZ
Yao Xue Xue Bao; 1993; 28(1):17-21. PubMed ID: 8328264
[TBL] [Abstract][Full Text] [Related]
18. Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
Cory JG; Downes DL; Cory AH; Schaper KJ; Seydel JK
Anticancer Res; 1994; 14(3A):875-9. PubMed ID: 8074487
[TBL] [Abstract][Full Text] [Related]
19. Antimalarial activities of polyhydroxyphenyl and hydroxamic acid derivatives.
Holland KP; Elford HL; Bracchi V; Annis CG; Schuster SM; Chakrabarti D
Antimicrob Agents Chemother; 1998 Sep; 42(9):2456-8. PubMed ID: 9736585
[TBL] [Abstract][Full Text] [Related]
20. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
